Annual Report Reveals $546M Net Loss Driven by Major Restructuring and Asset Impairments
PACB sits 94% above its 52-week low of $0.851.
Summary
Pacific Biosciences reported a $546.4 million net loss for 2025, largely due to $383.1 million in non-cash restructuring charges and asset impairments as it pivots away from short-read sequencing technology. The company also announced a $50.0 million asset sale to Illumina post-period.
Key Events · Earnings and Guidance · PACB
-
Significant Net Loss Driven by Restructuring
The company reported a net loss of $546.4 million for fiscal year 2025, a 76% increase from 2024, primarily due to $383.1 million in non-cash restructuring-related charges.
-
Major Asset Impairments and Strategic Pivot
Restructuring charges include $359.3 million in accelerated amortization of Omniome developed technology and $15.0 million in IPR&D impairment, reflecting a decision to cease development of the high-throughput short-read sequencing platform.
-
Asset Sale to Illumina Post-Period
Subsequent to year-end, on January 30, 2026, the company completed the disposition of its short-read DNA sequencing technology assets to Illumina Cambridge Limited for $50.0 million in cash, with net proceeds of $48.1 million.
-
Improved Cash Burn from Operations
Cash used in operating activities improved to $111.2 million in 2025 from $206.1 million in 2024, and the company believes it has sufficient liquidity for the next 12 months.
Analysis · PACB · Industrial Applications And Services
Pacific Biosciences of California, Inc.'s annual report for fiscal year 2025 highlights a substantial net loss of $546.4 million, a significant increase from the prior year, primarily due to $383.1 million in non-cash restructuring-related charges. These charges include accelerated amortization of developed technology from the 2021 Omniome acquisition and impairment of in-process research and development (IPR&D) assets, stemming from a strategic decision to cease development of its high-throughput short-read sequencing platform. While total revenue saw a modest 4% increase and cash used in operating activities improved, the large non-cash write-downs reflect a major strategic pivot and a re-evaluation of past investments. The subsequent sale of short-read DNA sequencing technology to Illumina for $50.0 million provides a cash infusion and further solidifies the company's focus on its HiFi long-read sequencing technology. The company states it has sufficient liquidity for the next 12 months, but the significant losses and strategic shift indicate ongoing challenges and a need for successful execution of its revised strategy.
At the time of this filing, PACB was trading at $1.65 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $492.1M. The 52-week trading range was $0.85 to $2.73. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.